Aetna modified CPB 0944 for sufentanil sublingual tablet (Dsuvia), effective December 10, 2025. Here's what billing teams need to know before submitting a single claim.
Aetna, a CVS Health company, updated CPB 0944 under its commercial medical plan coverage policy for Dsuvia — the single-dose sufentanil sublingual tablet used for acute pain management in supervised healthcare settings. The policy is unambiguous: Aetna considers Dsuvia not medically necessary for its primary labeled indication, and experimental or investigational for everything else. If your facility or practice has been billing for this drug under any acute pain diagnosis codes in the G89.1x range, this policy change has direct financial exposure for you.
Quick-Reference Table
| Field | Detail |
|---|---|
| Payer | Aetna |
| Policy | Sufentanil Sublingual Tablet (Dsuvia) — CPB 0944 |
| Policy Code | CPB 0944 |
| Change Type | Modified |
| Effective Date | December 10, 2025 |
| Impact Level | High |
| Specialties Affected | Emergency medicine, anesthesiology, pain management, acute care facilities, ambulatory surgery centers |
| Key Action | Stop billing Dsuvia for any acute pain diagnosis under Aetna commercial plans; flag existing claims for review before they hit a denial queue |
Aetna Dsuvia Coverage Criteria and Medical Necessity Requirements 2025
The short version: there are none. Aetna's Dsuvia coverage policy does not recognize a covered indication for this drug.
Under CPB 0944, Aetna states that sufentanil sublingual tablet does not meet medical necessity criteria for acute pain severe enough to require an opioid analgesic — which is, notably, the exact indication the FDA approved Dsuvia for in the first place. The policy cites unestablished safety data as the basis. That's a notable position given that Dsuvia carries FDA approval specifically for that indication, but Aetna is drawing a harder line here than the FDA label.
The policy does not describe a prior authorization pathway for this drug under Aetna commercial plans. Dsuvia is classified as not medically necessary, which typically forecloses a PA override. If your billing team has been assuming a prior authorization request would resolve coverage questions on Dsuvia claims, that assumption is likely wrong under this policy — but confirm PA applicability with Aetna directly before drawing a final conclusion.
Given the not medically necessary determination, claims for Dsuvia under Aetna commercial plans are expected to be denied. Confirm reimbursement expectations with your Aetna provider relations contact or contract. Any claim submitted with Dsuvia and a diagnosis code in the G89.1x range will face scrutiny on medical necessity grounds.
Aetna Sufentanil Sublingual Tablet Exclusions and Non-Covered Indications
Aetna's CPB 0944 draws a clean line through every potential use case for Dsuvia — the primary indication and anything beyond it.
For the primary use — acute pain severe enough to require an opioid — Aetna finds the safety profile insufficiently established to support medical necessity. This is the drug's core indication. Blocking coverage here effectively blocks the drug entirely under commercial plans governed by this policy.
For all other indications, Aetna goes a step further and classifies Dsuvia as experimental, investigational, or unproven. The reasoning is the same: lack of peer-reviewed published evidence establishing safety and effectiveness. In practice, this means no off-label use case survives this policy either.
This is a total exclusion policy, not a partial one. There is no clinical scenario described in CPB 0944 under which Dsuvia is covered.
Coverage Indications at a Glance
| Indication | Status | Relevant Codes | Notes |
|---|---|---|---|
| Acute pain severe enough to require an opioid analgesic (primary FDA-approved indication) | Not Covered — Not Medically Necessary | G89.11–G89.18 | Safety not established per Aetna; no prior auth pathway described in the policy |
| All other indications (off-label use) | Not Covered — Experimental, Investigational, or Unproven | G89.11–G89.18 | Safety and effectiveness not established in peer-reviewed literature |
Aetna Dsuvia Billing Guidelines and Action Items 2025
This policy has a hard effective date of December 10, 2025. Here's what your billing team needs to do.
| # | Action Item |
|---|---|
| 1 | Audit claims billed on or after December 10, 2025. Pull any Aetna commercial claims that include Dsuvia billing alongside diagnosis codes G89.11 through G89.18. Flag them for review before they hit a denial cycle. The earlier you catch these, the less time you spend on appeals. |
| 2 | Remove Dsuvia from your Aetna charge capture pathways. If your emergency department, ASC, or acute care facility has Dsuvia in your charge description master (CDM) as a billable item under Aetna commercial plans, take it out. Leaving it active invites claim denial without any realistic path to reimbursement. |
| 3 | Do not submit prior authorization requests expecting approval. The policy classifies this drug as not medically necessary — not as a drug that requires prior auth to unlock. Confirm with Aetna directly whether a PA pathway exists, but do not assume one will override the medical necessity determination under CPB 0944. |
| 4 | Check your contracted payer mix. CPB 0944 applies to Aetna commercial medical plans. If your patients have Aetna Medicare Advantage or Medicaid managed care plans administered by Aetna, confirm whether this CPB applies to those plan types or whether separate policies govern those members. |
| 5 | Notify your medical staff. Your physicians and advanced practice providers ordering Dsuvia in supervised settings need to know that Aetna commercial plan patients will not generate reimbursement for this drug. This is a supply chain and drug formulary conversation as much as a billing one. Loop in your pharmacy and your medical director. |
| 6 | Review any pending or denied claims that predate December 10, 2025. If you have claims in the pipeline from before the effective date, the old version of CPB 0944 governed those. Check what that version said. If the prior policy was less restrictive, you may have a narrower window to appeal on older claims before this version becomes the operative standard. |
| 7 | If you're unsure how this applies to your specific plan contracts, talk to your compliance officer. Some Aetna commercial plans have carve-outs or supplemental agreements that modify standard CPB applicability. Your compliance officer or billing consultant should verify whether your facility's specific contracts change anything here. |
| Previous Version | Current Version |
|---|---|
| Coverage is considered experimental and investigational for all indications | Coverage is considered medically necessary when specific criteria are met |
| Prior authorization is not required | Prior authorization is required for initial treatment |
| Documentation must include clinical history | Documentation must include clinical history |
| Re-review every 24 months | Re-review every 12 months with updated clinical documentation |
CPT, HCPCS, and ICD-10 Codes for Sufentanil Sublingual Tablet Under CPB 0944
The policy data for CPB 0944 does not list specific CPT or HCPCS drug billing codes. This is worth flagging for your billing team: when a drug policy doesn't enumerate specific J-codes or Q-codes, it means the coverage determination applies regardless of which billing code you use to represent the drug. The coverage exclusion travels with the drug, not the code.
Work with your pharmacy billing team to identify the specific HCPCS J-code your facility uses to bill Dsuvia, and map it against Aetna commercial plan claims. That code — whatever it is in your CDM — is the one your team needs to flag.
Key ICD-10-CM Diagnosis Codes Listed in CPB 0944
These are the acute pain diagnosis codes Aetna references in this policy. All eight fall under the Not Covered / Not Medically Necessary determination. Aetna does not differentiate between specific acute pain subtypes in this policy — every G89.1x code carries the same generic "Acute pain" label in CPB 0944.
| Code | Description |
|---|---|
| G89.11 | Acute pain |
| G89.12 | Acute pain |
| G89.13 | Acute pain |
| G89.14 | Acute pain |
| G89.15 | Acute pain |
| G89.16 | Acute pain |
| G89.17 | Acute pain |
| G89.18 | Acute pain |
Any of these codes paired with Dsuvia on an Aetna commercial claim is a denial waiting to happen. Build that logic into your claim scrubber now.
The Bigger Picture on This Policy
The real issue here isn't just the denial risk on individual claims — it's what this policy signals about opioid analgesic coverage for newer delivery formats.
Dsuvia was designed specifically for supervised clinical settings — emergency departments, procedural suites, post-op recovery areas. It has a specific REMS program precisely because it's intended for controlled environments where a clinician is present. Aetna's decision to classify even that tightly supervised, FDA-approved indication as not medically necessary is a significant stance.
This isn't the first time a payer has moved faster than the FDA in restricting an opioid product. Watch for similar coverage policy tightening from UnitedHealthcare and Cigna Healthcare on newer opioid formulations in 2026. When Aetna takes a hard position like this, other major commercial payers often follow within 12–18 months.
If you're managing a pain management practice, an ASC, or a hospital ED that sees Aetna commercial patients regularly, this policy deserves a conversation with your medical director and your clinical pharmacy team — not just your billing team.
Get the Full Picture
Track this policy across versions, search 1,500+ policies by CPT code, and get real-time alerts when any payer changes coverage.